CY1119995T1 - Βιοσυνθετικο συστημα που παραγει ανοσογονους πολυσακχαριτες σε προκαρυωτικα κυτταρα - Google Patents
Βιοσυνθετικο συστημα που παραγει ανοσογονους πολυσακχαριτες σε προκαρυωτικα κυτταραInfo
- Publication number
- CY1119995T1 CY1119995T1 CY20181100264T CY181100264T CY1119995T1 CY 1119995 T1 CY1119995 T1 CY 1119995T1 CY 20181100264 T CY20181100264 T CY 20181100264T CY 181100264 T CY181100264 T CY 181100264T CY 1119995 T1 CY1119995 T1 CY 1119995T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prokaryotic cells
- directed
- biosynthetic system
- glycosylated proteins
- immunogenic polysaccharides
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 230000001851 biosynthetic effect Effects 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 1
- 210000001236 prokaryotic cell Anatomy 0.000 title 1
- 108091006036 N-glycosylated proteins Proteins 0.000 abstract 3
- 150000002482 oligosaccharides Polymers 0.000 abstract 2
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 abstract 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 abstract 1
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27293109P | 2009-11-19 | 2009-11-19 | |
| PCT/US2010/002980 WO2011062615A1 (en) | 2009-11-19 | 2010-11-16 | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119995T1 true CY1119995T1 (el) | 2018-12-12 |
Family
ID=44059888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100264T CY1119995T1 (el) | 2009-11-19 | 2018-03-02 | Βιοσυνθετικο συστημα που παραγει ανοσογονους πολυσακχαριτες σε προκαρυωτικα κυτταρα |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8846342B2 (enExample) |
| EP (1) | EP2501406B8 (enExample) |
| JP (2) | JP5968784B2 (enExample) |
| KR (1) | KR101855380B1 (enExample) |
| CN (1) | CN102724997B (enExample) |
| AU (1) | AU2010322454B2 (enExample) |
| CA (1) | CA2780487C (enExample) |
| CY (1) | CY1119995T1 (enExample) |
| DK (1) | DK2501406T3 (enExample) |
| ES (1) | ES2660227T3 (enExample) |
| HR (1) | HRP20180338T1 (enExample) |
| HU (1) | HUE038456T2 (enExample) |
| IL (1) | IL219733A (enExample) |
| LT (1) | LT2501406T (enExample) |
| NO (1) | NO2501406T3 (enExample) |
| PL (1) | PL2501406T3 (enExample) |
| PT (1) | PT2501406T (enExample) |
| SI (1) | SI2501406T1 (enExample) |
| TR (1) | TR201803015T4 (enExample) |
| WO (1) | WO2011062615A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1481057T3 (da) * | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| NO2501406T3 (enExample) * | 2009-11-19 | 2018-05-19 | ||
| EP2742355B1 (en) * | 2011-08-12 | 2018-12-19 | The Governors of the University of Alberta | Method of diagnosing bacterial infections using bacterial glycoproteins |
| CA2879272A1 (en) | 2012-07-16 | 2014-01-23 | Robert G.K. DONALD | Saccharides and uses thereof |
| US20150353940A1 (en) | 2013-08-05 | 2015-12-10 | Absci, Llc | Vectors for use in an inducible coexpression system |
| EP2724730A1 (en) | 2012-10-29 | 2014-04-30 | Institut Pasteur | Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri |
| HUE038915T2 (hu) | 2013-01-17 | 2018-12-28 | Arsanis Biosciences Gmbh | MDR E. colira fajlagos antitest |
| GB201301085D0 (en) * | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| BR112016007727A8 (pt) * | 2013-10-11 | 2018-01-30 | Glycovaxyn Ag | célula hospedeira, e, método para produzir uma proteína n-glicosilada. |
| NZ723328A (en) | 2014-02-24 | 2018-01-26 | Glycovaxyn Ag | Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture |
| MX378857B (es) * | 2014-04-17 | 2025-03-10 | Glaxosmithkline Biologicals Sa | Celulas huespedes modificadas y usos de las mismas. |
| KR101629656B1 (ko) * | 2014-10-24 | 2016-06-14 | 충남대학교산학협력단 | 면역증강효과를 갖는 수용성 다당체 및 이를 함유하는 조성물 |
| SI3240895T1 (sl) * | 2014-12-30 | 2022-04-29 | Glaxosmithkline Biologicals S.A. | Sestavki in postopki za glikozilacijo proteinov |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| EP3384018A1 (en) | 2015-11-30 | 2018-10-10 | Limmatech Biologics AG | Methods of producing glycosylated proteins |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| JP7551618B2 (ja) | 2018-12-12 | 2024-09-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｏ－結合型グリコシル化のための修飾キャリアタンパク質 |
| CR20210522A (es) | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CA3185719A1 (en) | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
| US20230226175A1 (en) | 2020-06-25 | 2023-07-20 | Glaxosmithkline Biologicals Sa | Modified exotoxin a proteins |
| PE20231385A1 (es) | 2020-09-17 | 2023-09-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y usos de las mismas |
| CN112877246B (zh) * | 2021-02-23 | 2022-01-18 | 山东省滨州畜牧兽医研究院 | 一种高效制备霍乱弧菌菌影的方法 |
| CN115747239A (zh) * | 2021-09-03 | 2023-03-07 | 上海交通大学 | 用于表达黏蛋白型o-糖基化蛋白的原核载体和系统、黏蛋白型o-糖基化蛋白的制备方法 |
| EP4452308A1 (en) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60142915A (ja) * | 1983-12-28 | 1985-07-29 | Lion Corp | 口腔用組成物 |
| EP0170204B1 (de) | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
| US5242809A (en) * | 1986-02-28 | 1993-09-07 | Smithkline Beecham Corporation | Gal operon of streptomyces |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| US5665559A (en) * | 1989-05-18 | 1997-09-09 | The United States Of America As Represented By The Secretary Of The Navy | Production of monoclonal antibodies to bacteroides gingivalis by hybridoma BGII, VF9/2D |
| US5280113A (en) * | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
| AU6663294A (en) | 1993-05-14 | 1994-12-12 | Upjohn Company, The | Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase |
| US6365723B1 (en) * | 1998-12-04 | 2002-04-02 | Wisconsin Alumni Research Foundation | Sequences of E. coli O157 |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| EP1399538A2 (en) | 1999-03-02 | 2004-03-24 | Human Genome Sciences, Inc. | Engineering intracellular sialylation pathways |
| NZ522320A (en) | 2000-05-12 | 2007-03-30 | Neose Technologies Inc | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| EP2028275A3 (en) | 2000-06-30 | 2009-05-06 | VIB vzw | Protein glycosylation modification in pichia pastoris |
| US20040067557A1 (en) * | 2000-12-21 | 2004-04-08 | Tetsuo Endo | Process for producing udp-n-acetylgalactosamine and sacciiaride containing n-acetylgalactosamine |
| US20020132320A1 (en) * | 2001-01-10 | 2002-09-19 | Wang Peng George | Glycoconjugate synthesis using a pathway-engineered organism |
| US20020150968A1 (en) * | 2001-01-10 | 2002-10-17 | Wang Peng G. | Glycoconjugate and sugar nucleotide synthesis using solid supports |
| US6696814B2 (en) | 2001-07-09 | 2004-02-24 | Tyco Electronics Corporation | Microprocessor for controlling the speed and frequency of a motor shaft in a power tool |
| US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| US7541043B2 (en) * | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| JP4727927B2 (ja) * | 2002-03-07 | 2011-07-20 | アイトゲネシシェ・テッヒニシェ・ホーホシューレ・チューリッヒ | 原核宿主における組換えグリコシル化タンパク質産生のためのシステムおよび方法 |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| CN1671722A (zh) | 2002-08-01 | 2005-09-21 | 加拿大国家研究院 | 弯曲菌的聚糖和糖肽 |
| EP2657251B1 (en) | 2004-05-24 | 2018-03-21 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Live, oral vaccine for protection against Shigella dysenteriae serotype 1 |
| JP5235657B2 (ja) * | 2005-03-24 | 2013-07-10 | バイオジェネリックス ゲーエムベーハー | 原核生物における可溶性活性真核生物グリコシルトランスフェラーゼの発現 |
| ES2535084T3 (es) | 2005-05-11 | 2015-05-05 | Eth Zurich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
| US20070202578A1 (en) * | 2005-08-26 | 2007-08-30 | Centre National De La Recherche Scientifique (Cnrs) | Production of globosides oligosaccharides using metabolically engineered microorganisms |
| WO2009089154A2 (en) * | 2008-01-03 | 2009-07-16 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
| CN102037004A (zh) * | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| SI2257307T1 (sl) * | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| CN102365359B (zh) * | 2009-03-27 | 2014-10-29 | 瑞士联邦苏黎世技术大学 | 呈递空肠弯曲杆菌n-聚糖或其衍生物的肠沙门氏菌 |
| GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
| NO2501406T3 (enExample) * | 2009-11-19 | 2018-05-19 | ||
| CA2789505C (en) * | 2010-02-11 | 2017-12-05 | The Governors Of The University Of Alberta | N-linked glycan compounds |
| WO2011138361A1 (en) * | 2010-05-06 | 2011-11-10 | Glycovaxyn | Capsular gram-positive bacteria bioconjugate vaccines |
| WO2012027850A1 (en) * | 2010-09-03 | 2012-03-08 | Christine Szymanski | Peptide containing multiple n-linked glycosylation sequons |
| WO2013019625A2 (en) * | 2011-07-29 | 2013-02-07 | The University Of Wyoming | Methods of using a bacterial glcnac-6-p 2'-epimerase to promote sialylation of glycoconjugates |
| CA2847621A1 (en) * | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| EP2917351B1 (en) * | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| GB201301085D0 (en) * | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
-
2010
- 2010-11-16 NO NO10831896A patent/NO2501406T3/no unknown
- 2010-11-16 PL PL10831896T patent/PL2501406T3/pl unknown
- 2010-11-16 DK DK10831896.5T patent/DK2501406T3/en active
- 2010-11-16 CN CN201080061239.XA patent/CN102724997B/zh active Active
- 2010-11-16 CA CA2780487A patent/CA2780487C/en active Active
- 2010-11-16 KR KR1020127015728A patent/KR101855380B1/ko active Active
- 2010-11-16 EP EP10831896.5A patent/EP2501406B8/en active Active
- 2010-11-16 HU HUE10831896A patent/HUE038456T2/hu unknown
- 2010-11-16 TR TR2018/03015T patent/TR201803015T4/tr unknown
- 2010-11-16 SI SI201031641T patent/SI2501406T1/en unknown
- 2010-11-16 LT LTEP10831896.5T patent/LT2501406T/lt unknown
- 2010-11-16 AU AU2010322454A patent/AU2010322454B2/en active Active
- 2010-11-16 US US13/510,859 patent/US8846342B2/en active Active
- 2010-11-16 HR HRP20180338TT patent/HRP20180338T1/hr unknown
- 2010-11-16 WO PCT/US2010/002980 patent/WO2011062615A1/en not_active Ceased
- 2010-11-16 ES ES10831896.5T patent/ES2660227T3/es active Active
- 2010-11-16 PT PT108318965T patent/PT2501406T/pt unknown
- 2010-11-16 JP JP2012539870A patent/JP5968784B2/ja active Active
-
2012
- 2012-05-10 IL IL219733A patent/IL219733A/en active IP Right Grant
-
2014
- 2014-08-18 US US14/462,261 patent/US9764018B2/en active Active
-
2016
- 2016-07-06 JP JP2016133786A patent/JP2017018098A/ja active Pending
-
2018
- 2018-03-02 CY CY20181100264T patent/CY1119995T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2501406A1 (en) | 2012-09-26 |
| IL219733A (en) | 2017-08-31 |
| CA2780487C (en) | 2019-05-21 |
| DK2501406T3 (en) | 2018-02-26 |
| JP2013511520A (ja) | 2013-04-04 |
| HUE038456T2 (hu) | 2018-10-29 |
| JP5968784B2 (ja) | 2016-08-10 |
| ES2660227T3 (es) | 2018-03-21 |
| EP2501406B8 (en) | 2018-01-24 |
| EP2501406B1 (en) | 2017-12-20 |
| AU2010322454B2 (en) | 2016-05-19 |
| US20150190492A1 (en) | 2015-07-09 |
| CA2780487A1 (en) | 2011-05-26 |
| LT2501406T (lt) | 2018-03-26 |
| KR101855380B1 (ko) | 2018-05-08 |
| JP2017018098A (ja) | 2017-01-26 |
| NO2501406T3 (enExample) | 2018-05-19 |
| SI2501406T1 (en) | 2018-03-30 |
| HRP20180338T1 (hr) | 2018-04-06 |
| US9764018B2 (en) | 2017-09-19 |
| AU2010322454A1 (en) | 2012-06-07 |
| TR201803015T4 (tr) | 2018-03-21 |
| CN102724997A (zh) | 2012-10-10 |
| IL219733A0 (en) | 2012-07-31 |
| US8846342B2 (en) | 2014-09-30 |
| EP2501406A4 (en) | 2013-04-24 |
| WO2011062615A1 (en) | 2011-05-26 |
| KR20120102086A (ko) | 2012-09-17 |
| PT2501406T (pt) | 2018-02-21 |
| US20130028926A1 (en) | 2013-01-31 |
| CN102724997B (zh) | 2016-09-21 |
| PL2501406T3 (pl) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120512T1 (el) | Βιοσυζευγματα κατασκευασμενα απο ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα | |
| CY1120319T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α | |
| MX2021011445A (es) | Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos. | |
| CY1119895T1 (el) | Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων | |
| EA201590705A1 (ru) | ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ | |
| CY1123651T1 (el) | Ολιγοσακχαριτης και διαδικασια παρασκευης αυτου | |
| CY1115801T1 (el) | Συζευγματα παραγοντα viii πολυμερους | |
| CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
| BR112015008052A2 (pt) | célula hospedeira, métodos para produzir um glicoconjugado e para produzir uma proteína n-glicosilada, e, glicoconjugado | |
| EA201691478A1 (ru) | Новый полисахарид и его применения | |
| PH12021550319A1 (en) | Escherichia coli compositions and methods thereof | |
| CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| CL2012002195A1 (es) | Composicion inmunogénica que comprende una mezcla de conjugados de polisacaridos-proteina multivalente que consiste en polisacáridos capsulares de streptococcus pneumoniae; metodo para inducir una respuesta inmune a un polisacarido capsular de streptococcus pneumoniae. | |
| JP2010215657A5 (enExample) | ||
| CL2011003273A1 (es) | Antígeno del virus respiratorio sincicial (vrs) recombinante, que comprende un polipéptido de proteína f soluble con una modificación que altera su glicosilación y que a su vez comprende un dominio f1 y un dominio f2 de proteína f de vrs; composición inmunogénica que lo comprende; ácido nucleico que lo codifica; vector; célula hospedera; método para producir dicho antígeno del vrs; y su uso para tratar una infección de vrs. | |
| CY1119113T1 (el) | Σκευασματα με βαση το υαλουρονικο οξυ | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| BR112018005746A2 (pt) | composições para higiene bucal e métodos de uso. | |
| TR201906398T4 (tr) | Salgı bezleriyle ilişkili virüs yapılarını içeren iletken hava yolu hücrelerinin hedeflenmesine yönelik bileşimler. | |
| RU2013114392A (ru) | Маленькие липосомы для доставки кодирующей иммуноген рнк | |
| NO20082930L (no) | Fremgangsmate for sol-gel prosessering | |
| EA201190283A1 (ru) | Мультивалентный адъювантный дисплей | |
| MX2009008928A (es) | Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas. | |
| CY1117636T1 (el) | Χαμηλου-μοριακου-βαρους βιοτεχνολογικη 6-θειικη χονδροϊτινη για την προληψη της οστεοαρθριτιδας | |
| CY1122281T1 (el) | Μεθοδος παραγωγης προϊοντων με βαση το κρεας που περιεχουν ελαιο, η οποια περιλαμβανει πρωτοκολλο απευθειας προσθηκης του ελαιου |